tirzepatide wegovy vs. Semaglutide for Weight Loss Zepbound (tirzepatide) superior to Wegovy

The incidence of gastrointestinal adverse events was 72.5% with CagriSema versus 34.4% with placebo, predominantly transient and mild to moderate in severity

Salt Lake clinic : 801-758-2130

Results from one study found that semaglutide reduced the risk of major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, compared to a placebo.* 5

Those with numbers above 6.5% are considered diabetic and require treatment and lifestyle changes to lower blood sugar levels

For those in Montana requiring stronger weight loss effects, Zepbound could be the right option

C'est quoi l'Ozempic